Brown Advisory’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-226,734
| Closed | -$17.3M | – | 1321 |
|
|
2018
Q3 | $17.3M | Sell |
226,734
-177,079
| -44% | -$13.5M | 0.05% | 269 |
|
|
2018
Q2 | $31M | Buy |
403,813
+683
| +0.2% | +$52.5K | 0.1% | 193 |
|
|
2018
Q1 | $20.6M | Buy |
403,130
+49,828
| +14% | +$2.54M | 0.07% | 228 |
|
|
2017
Q4 | $16.4M | Buy |
353,302
+11,600
| +3% | +$538K | 0.05% | 257 |
|
|
2017
Q3 | $18.2M | Buy |
341,702
+19,205
| +6% | +$1.02M | 0.06% | 237 |
|
|
2017
Q2 | $20M | Buy |
322,497
+4,687
| +1% | +$291K | 0.06% | 229 |
|
|
2017
Q1 | $21.5M | Buy |
317,810
+19,567
| +7% | +$1.33M | 0.07% | 208 |
|
|
2016
Q4 | $21M | Buy |
298,243
+16,870
| +6% | +$1.19M | 0.07% | 203 |
|
|
2016
Q3 | $20M | Buy |
281,373
+19,790
| +8% | +$1.4M | 0.07% | 199 |
|
|
2016
Q2 | $12.8M | Buy |
261,583
+61,526
| +31% | +$3.01M | 0.04% | 254 |
|
|
2016
Q1 | $12.7M | Buy |
200,057
+85,935
| +75% | +$5.44M | 0.04% | 239 |
|
|
2015
Q4 | $12.8M | Buy |
114,122
+4,584
| +4% | +$514K | 0.04% | 239 |
|
|
2015
Q3 | $10.6M | Buy |
109,538
+2,604
| +2% | +$251K | 0.04% | 267 |
|
|
2015
Q2 | $10.9M | Sell |
106,934
-14,906
| -12% | -$1.53M | 0.04% | 269 |
|
|
2015
Q1 | $7.56M | Buy |
121,840
+37,380
| +44% | +$2.32M | 0.02% | 306 |
|
|
2014
Q4 | $3.71M | Buy |
84,460
+64,728
| +328% | +$2.84M | 0.01% | 388 |
|
|
2014
Q3 | $1.12M | Sell |
19,732
-227
| -1% | -$12.9K | ﹤0.01% | 527 |
|
|
2014
Q2 | $896K | Sell |
19,959
-16
| -0.1% | -$718 | ﹤0.01% | 575 |
|
|
2014
Q1 | $977K | Buy |
+19,975
| New | +$977K | ﹤0.01% | 544 |
|